Actively Recruiting
ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Led by Hospital of Macerata · Updated on 2025-11-26
534
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Study wants to explore real-world data in three distinct settings * Patients with metachronous or de novo mCSPC treated with ADT+ARSI or ADT+ARSI+docetaxel \_ARON-3S * Patients receiving Lutetium-177 PSMA for mCRPC \_ ARON-3Lu * Patients treated with PARP inhibitors (alone or combined with ARSI) for CRPC \_ ARON-3GEN
CONDITIONS
Official Title
ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients With Metastatic PCa
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged >18 years
- Cytological or histological diagnosis of prostate cancer
- Histologically or radiologically confirmed metastatic disease
- For ARON-3S: Treatment with ADT plus Apalutamide, Enzalutamide, Abiraterone, Abiraterone plus Docetaxel, or Darolutamide plus Docetaxel (including prior docetaxel treatment as per CHAARTED)
- For ARON-3Lu: Treatment with Lutetium-177-PSMA therapy for castration-resistant prostate cancer
- For ARON-3GEN: HRD positive status
- Treatment with PARP inhibitors for castration-resistant prostate cancer including olaparib (1st to 3rd line), olaparib plus abiraterone (1st line), niraparib plus abiraterone (1st line), or talazoparib plus enzalutamide
You will not qualify if you...
- Patients without histologically confirmed diagnosis of prostate cancer
- Patients without histologically or radiologically confirmed metastatic disease
- For ARON-3S: Patients treated with doublets or triplets not listed in the inclusion criteria
- For ARON-3Lu: Patients treated with Lutetium-177-PSMA therapy for hormone/castration-sensitive prostate cancer
- For ARON-3GEN: HRD negative status
- Patients treated with PARP inhibitors alone or in combination regimens not included in the ARON-3GEN study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ospedale di Macerata
Province of Macerata, Macerata, Italy, 62100
Actively Recruiting
Research Team
M
Matteo Santoni
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here